Tag Archives: Johnson & Johnson

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?

News: Pfizer Inc.’s (New York City) key pneumococcal vaccine, Prevnar, whose sales soared through 2015, stumbled in fourth-quarter results (pdf) released last week. The blockbuster inoculation fell significantly short of Street… Read more »

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

J&J finally captures Actelion for $30 billion; deal looks good for both unless “what ifs” bite pharma giant’s shareholders

The News: It took months but Swiss biotech Actelion Ltd. (Allschwil) said on Thursday (January 26, 2017) it had agreed to be purchased by Johnson & Johnson (New Brunswick NJ) in a… Read more »

Japan’s Takeda leads off 2017 M&A season with gutsy deal to buy US cancer specialist Ariad for $5.2 billion; it’s expensive, but probably worth it

Japan’s Takeda Pharmaceutical Co. Ltd. agreed to acquire Ariad Pharmaceuticals Inc. (Cambridge MA) for $24 per share in cash, or an enterprise value of approximately $5.2 billion, boosting its oncology… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »

Healthcare stocks primed for comeback in 2017? Here are Steve’s top picks

The population of the world, and the US and developed nations in particular, is growing and getting older, while the costs of keeping people healthy and living longer are exploding…. Read more »

Johnson & Johnson eyeing Actelion; who wouldn’t with a “pro-biotech” Trump administration?

Johnson & Johnson (New Brunswick NJ) said Friday (November 11, 2016) it is in “preliminary discussions” with Swiss drug company Actelion Pharmaceuticals Ltd. (Basel CHE), a deal that would help the… Read more »

Johnson & Johnson Tumbles as Pfizer Set to Launch Remicade Biosimilar; Solid 3rd Quarter Doesn’t Quell Market’s Overreaction

Thriving pharmaceutical sales drove stellar quarterly results for Johnson & Johnson (New Brunswick NJ), but the company’s shares fell 3% so far this week on worries that its smash hit,… Read more »

Tenet to Pay $553 Million to Settle Kickback Allegations; Culture of Corruption Dates Back Decades

Tenet Healthcare Corp. (Dallas TX) and two of its Atlanta subsidiaries have agreed to pay more than $513 million to resolve criminal and civil claims accusing the chain of paying… Read more »